Greenfire Bio

Greenfire Bio is a private, pre-revenue biotech company that functions as a specialized accelerator for early-stage oncology assets. Its business model involves acquiring or in-licensing late preclinical or early clinical programs, primarily first-in-class small molecules and novel vaccines, and advancing them through a virtual, asset-centric subsidiary structure. The company's current pipeline includes a Phase 1 SIK2/3 inhibitor for ovarian cancer and TNBC, an investment in a Phase 2 NMT inhibitor for AML and solid tumors, and a therapeutic vaccine platform for solid tumors. Greenfire's strategy is to build value by providing capital and expert development oversight, then monetizing assets through strategic partnerships, sales, or IPOs.

Operational and business development platform for in-licensing and accelerating early-stage, first-in-class oncology assets (small molecules and therapeutic vaccines) via a virtual, subsidiary-based model.

Greenfire competes with other biotech accelerators, venture capital firms, and large pharma business development teams for high-quality early-stage assets. Its pipeline assets face intense competition within their respective oncology indications from both established therapies and numerous novel modalities in development.